Researchers discover new treatment possibilities for Lou Gehrig's disease

April 17, 2013
Montreal researchers discover new treatment possibilities for Lou Gehrig's disease

(Medical Xpress)—A team led by Dr. Alex Parker, a professor of pathology and cellular biology and a researcher at the University of Montreal Hospital Research Centre (CRCHUM), has identified an important therapeutic target for alleviating the symptoms of Lou Gehrig's disease, also known as amyotrophic lateral sclerosis (ALS), and other related neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and Huntington's disease.

In a study published in the online version of Neurobiology of Disease, the team both confirmed the importance of this new target as well as a series of compounds that can be used to attenuate the dysregulation of one of the important cellular processes that lead to and ultimately to .

Although scientists are unclear about causes of ALS, they have made headway in identifying the cellular process potentially implicated in disease onset and progression. One such process which has attracted researcher interest involves the endoplasmic reticulum (ER), a component of cells that plays an important role in maintaining cell health. In collaboration with Dr. Pierre Drapeau at the University of Montreal and using worm and zebrafish models of ALS, Parker's team not only confirmed that incapacitated ER leads to the motor typical of ALS, but also identified a series of compounds that alleviate the fatal consequences of defective ER.

"Since Riluzole, the one approved treatment compound for treating ALS, only has a modest effect on slowing disease progression, we set out to test a number of other compounds, and in so doing we discovered that they work by compensating for defective ER" explains Dr Parker. The compounds in question, Methylene blue, Salubrinal, Guanabenz and Phenazine, were each tested individually and in different combinations.

With the exception of Phenazine, these compounds have known benefits for treating . Parker and his team showed that each of these compounds reduces paralysis and neurodegeneration and that each acts on different parts of the ER pathway to achieve neuroprotection. More importantly, the researchers found that using these in different combinations can enhance their therapeutic effects.

"These results are quite encouraging," says Dr Parker, "and have given us a much better understanding of ER's role in ALS as well as showing the way for improved treatments". Parker's team plans to test and confirm these findings with more complex animal models, a necessary step in developing medication that can be of benefit to human beings.

About amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis is an adult onset neurodegenerative disorder characterized by a progressive and selective loss of motor neurons in the motor cortex, the brainstem and the spinal cord, leading to rapidly progressing weakness, muscle atrophy, muscle spasticity and difficulty speaking, swallowing, and breathing. Most ALS patients die from respiratory failure. The disease, for which there is no known cure, affects about 1-3 people in 100,000. The etiology of ALS is composed of both genetic and environmental factors and its origins remain unknown for most cases. Its clinical development is extremely variable.

Explore further: Disease progression halted in rat model of Lou Gehrig's disease

More information: "Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo" was published on April 5, 2013 in the online version of Neurobiology of Diseases. An abstract of the article can be viewed on Pubmed: www.ncbi.nlm.nih.gov/pubmed/23567652.

Related Stories

Disease progression halted in rat model of Lou Gehrig's disease

December 12, 2011
Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's disease) is an incurable adult neurodegenerative disorder that progresses to paralysis and death. Genetic mutations are the cause of disease in 5% of patients ...

Scientists identify new gene that influences survival in amyotrophic lateral sclerosis

August 26, 2012
A team of scientists, including faculty at the University of Massachusetts Medical School (UMMS), have discovered a gene that influences survival time in amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). ...

Potential new drug target in Lou Gehrig's disease

November 14, 2011
Two proteins conspire to promote a lethal neurological disease, according to a study published online this week in the Journal of Experimental Medicine.

Recommended for you

Brain stimulation may improve cognitive performance in people with schizophrenia

July 24, 2017
Brain stimulation could be used to treat cognitive deficits frequently associated with schizophrenia, according to a new study from King's College London.

New map may lead to drug development for complex brain disorders, researcher says

July 24, 2017
Just as parents are not the root of all their children's problems, a single gene mutation can't be blamed for complex brain disorders like autism, according to a Keck School of Medicine of USC neuroscientist.

Bird songs provide insight into how developing brain forms memories

July 24, 2017
Researchers at the University of Chicago have demonstrated, for the first time, that a key protein complex in the brain is linked to the ability of young animals to learn behavioral patterns from adults.

Research identifies new brain death pathway in Alzheimer's disease

July 24, 2017
Alzheimer's disease tragically ravages the brains, memories and ultimately, personalities of its victims. Now affecting 5 million Americans, Alzheimer's disease is the sixth leading cause of death in the U.S., and a cure ...

Illuminating neural pathways in the living brain

July 24, 2017
Using light alone, scientists from the Max Planck Institute of Neurobiology in Martinsried are now able to reveal pairs or chains of functionally connected neurons under the microscope. The new optogenetic method, named Optobow, ...

Working around spinal injuries: Rehabilitation, drug treatment lets rats recover some involuntary movement

July 24, 2017
A new study in rats shows that changes in the brain after spinal cord injury are necessary to restore at least some function to lower limbs. The work was published recently in the journal eLife.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.